June 9, 2022

Department of Policies and Regulations
China National Medical Products Administration
No. 1, Beilu Yuan, Zhanlan Lu
Xicheng District
Beijing, People’s Republic of China
100037

Via Email: zfsfgc@nmpa.gov.cn


Dear China National Medical Products Administration:

The Intellectual Property Owners Association (IPO) appreciates the opportunity to respond to the request for comments on the Regulations for the Implementation of the Drug Administration Law of the People's Republic of China (Draft Amendment for Comments) (“Draft Regulations”) published on 9 May 2022.

IPO is an international trade association representing a “big tent” of diverse companies, law firms, service providers and individuals in all industries and fields of technology that own, or are interested in, intellectual property (IP) rights. IPO membership includes over 125 companies and spans over 30 countries. IPO advocates for effective and affordable IP ownership rights and offers a wide array of services, including supporting member interests relating to legislative and international issues; analyzing current IP issues; providing information and educational services; supporting and advocating for diversity, equity, and inclusion in IP and innovation; and disseminating information to the public on the importance of IP rights.

IPO’s vision is the global acceleration of innovation, creativity, and investment necessary to improve lives. The Board of Directors has adopted a strategic objective to foster diverse engagement in the innovation ecosystem and to integrate diversity, equity, and inclusion in all its work to complement IPO’s mission of promoting high quality and enforceable IP rights and predictable legal systems for all industries and technologies.

IPO is grateful for the opportunity to share feedback and appreciates the aim of the Draft Regulations to strengthen data exclusivity during regulatory review of drugs and protect the legitimate rights and interests of drug patentees and the public. We hope that our comments below will be helpful during the process of finalizing the Draft Regulations.
Rule 38

Under Rule 38 paragraph 1, “if no effective judgment, ruling, mediation certification or administrative adjudication is obtained beyond a certain period, the medical products administration department under the State Council can approve the marketing of the drug.”

According to Article 9 paragraph 2 item (4) of Measures for Implementation of Early Resolution Mechanisms for Drug Patent Disputes (For Trial Implementation) (“Trial Measures”) issued by China National Medical Products Administration (CNMPA) together with China National Intellectual Property Administration (CNIPA), in such a situation where no effective judgment, ruling, mediation certification or administrative adjudication is obtained beyond a certain period, “the related chemical generic drug registration application shall be transferred to the administrative examination and approval step according to the procedure.”

Accordingly, IPO suggests the following revision to Rule 38 for consistency with the Trial Measures:

Where a patent right is disputed during drug registration application, the party may take legal action before a people's court or file a request for administrative adjudication with the patent administration department under the State Council, during which the drug technical review is not stopped. For a chemical drug that has passed the technical review, the medical products administration department under the State Council shall make a decision as to whether the marketing of the drug is approved, in accordance with the effective judgment, ruling or mediation certification from the people's court or the administrative adjudication from the patent administration department under the State Council; if no effective judgment, ruling, mediation certification or administrative adjudication is obtained beyond a certain period, the medical products administration department under the State Council can approve the marketing of the drug.

The related chemical drug registration application shall be transferred to the administrative examination and approval step according to the procedure. The medical products administration department under the State Council shall establish the registration platform of drug patent information. Drug registration applicants and drug marketing authorization holders shall register related drug patent information according to the regulation, and specify the related drug patents involved and the status thereof. The drug registration applicants and the drug marketing authorization holders shall be responsible for the authenticity, accuracy and completeness of the information registered by them.

Rule 39

Rule 39 states that “[t]he State encourages the development of generic drugs,” without reference to encouraging development of new drugs. Article 5 of the Drug Administration Law, however, stipulates that “[t]he State encourages the research and
creation of new drugs, and protects the legitimate rights and interests of citizens, legal
persons and other organizations to research and develop new drugs.” Therefore, IPO
suggests that, to ensure that Rule 39 of the Draft Regulations is consistent with Article 5 of
the Drug Administration Law, that the language referencing the development of generic
drugs be removed from Article 39 or, alternatively, that the following language be added to
Rule 39:

The State encourages the development of generic drugs, but with
appropriate protections for innovators, as the State encourages the
research and creation of new drugs, and protects the legitimate rights and
interests of citizens, legal persons and other organizations to research and
develop new drugs. For the chemical generic drug that is the first to have
successful challenge to the patent and is the first to have been approved for
marketing, a market exclusivity period shall be granted. The medical
products administration department under the State Council shall not
approve the marketing of generic drugs of the same variety within 12
months from the date of approval of the drug, except for those who
successfully jointly challenge the patent. The market exclusivity period does
not exceed the original patent right term of the challenged drug.

Also under Rule 39, “[f]or the chemical generic drug that is the first to have
successful challenge to the patent and is the first to have been approved for marketing, a
market exclusivity period shall be granted.” According to Article 11 of the Trial Measures,
“[s]uccessful challenge to the patent’ means that the chemical generic drug applicant
submits the fourth type of certification, and, according to his or its request for invalidation
of the patent right, the related patent right is declared invalid, thus allowing the generic drug
to be approved for marketing.” IPO suggests clarifying the meaning of “successful
challenge to the patent” by including the definition from the Trial Measures within this Rule.

Therefore, IPO suggests the following addition:

“Successful challenge to the patent” means that the chemical generic
drug applicant submits the fourth type of certification, and, according to
his or its request for invalidation of the patent right, the related patent
right is declared invalid, thus allowing the generic drug to be approved
for marketing.

Rule 40

IPO welcomes the introduction of six-years “data exclusivity” under Rule 40, but
notes that such protection appears to be only for “undisclosed trial data and other data of
some drugs approved for marketing.” IPO suggests that the scope of data and drugs under
this Rule be better defined to include all undisclosed data included in drug registration
applications. IPO recommends further clarification or definitions regarding the meaning of
“other data” and “some drugs” in this Rule.
IPO also notes that the CNMPA may have authority to disclose the undisclosed trial data, “for the need of public interests.” The definition of “public interests” is not clear, and could be subject to different interpretations. If an incorrect interpretation of public interests was made, data exclusivity could be moot. IPO suggests that the meaning of “public interests” should be clarified. Further, CNMPA also has authority to disclose the undisclosed trial data, “where steps are taken to ensure that the data are protected against unfair commercial use.” IPO believes it would be helpful to clarify what such steps would be.

IPO thanks the China National Medical Products Administration for its attention to IPO’s comments submitted herein, and we welcome further dialogue and opportunity to provide additional comments. IPO has enclosed this letter as translated herewith.

Sincerely,

Karen Cochran
President
2022年6月9日

国家药品监督管理局政策法规司法规处
北京市西城区展览路北露园1号
邮政编码100037

电子邮箱: zfsfge@nmpa.gov.cn

主题: 药品管理法实施条例意见反馈(2022年6月9日)

致国家药品监督管理局:

美国知识产权所有人协会（下称“IPO协会”）感谢有机会对2022年5月9日发布的《中华人民共和国药品管理法实施条例（修订草案征求意见稿）》（下称《《修订草案》》）提交意见。

IPO协会是一家国际性行业协会。它是一个代表了各技术领域内拥有知识产权或对知识产权有兴趣的广泛的行业形形色色的公司，及个人。IPO的成员包括遍布30多个国家的125家公司。IPO协会倡导有效且负担得起的知识产权所有权，并提供广泛的服务，包括：支持与立法和国际问题相关的成员利益；分析当前的知识产权问题；提供信息和教育服务；支持和倡导知识产权和创新的多样性和公平性；向公众传播有关知识产权重要性的信息。

IPO的愿景是在全球加速改善所需的创新、创造力和投资。董事会已通过战略目标，以促进创新生态系统的多元化参与，并将多样性和公平性纳入所有工作，以补充IPO的促进所有行业和技术的高质量和可执行的知识产权和可预测的法律体系的使命。

IPO非常感激有机会分享反馈，并赞赏修订草案在加强药品监管审查过程中的试验数据独占权的目的，保护药品专利权人和公众的合法权益。我们希望下面的评论在最终确定《修改草案》的过程中有所帮助。
第38条

第三十八条第一款规定：“超过一定期限未取得生效判决、裁定、调解书或者行政裁决的，国务院药品监督管理部门可批准药品上市。”

根据国家药监局、国家知识产权局组织制定的《药品专利纠纷早期解决机制实施办法（试行）》（下称“《实施办法（试行）》”）第9条第二段（4），在超过一定期限未取得生效判决、裁定、调解书或者行政裁决的情况下，“按照程序将相关化学仿制药注册申请转入行政审批环节”。

故此，IPO建议下面的修改以使第38条与《实施办法（试行）》一致：

药品注册申请期间专利权存在纠纷的，当事人可以向人民法院提起诉讼或者向国务院专利行政部门申请行政裁决，期间不停止药品技术审评。对通过技术审评的化学药品，国务院药品监督管理部门根据生效判决、裁定或者调解书或者国务院专利行政部门行政裁决作出是否批准上市的决定；超过一定期限未取得生效判决、裁定、调解书或者行政裁决的，国务院药品监督管理部门可批准药品上市按照程序将相关化学仿制药注册申请转入行政审批环节。

国务院药品监督管理部门建立药品专利信息登记平台，药品注册申请人和药品上市许可持有人应当按规定登记药品专利相关信息，并说明涉及的相关药品专利及其权属状态。

药品注册申请人和药品上市许可持有人应当对其登记的专利信息的真实性、准确性和完整性负责。

第39条

第39条提及“国家鼓励仿制药发展”，而未提及鼓励开发新药。但是，中华人民共和国药品管理法第5条要求“国家鼓励研究和创制新药，保护公民、法人和其他组织研究、开发新药的合法权益。”。故此，IPO建议，为了让《修订草案》的第39条与中华人民共和国药品管理法第5条一致，移除第39条中关于仿制药发展的语句，或作为替代地，增加下面的语句：

国家鼓励仿制药发展，但对于创新者提供足够的保护，因为国家国家鼓励新药研发，保护公民、法人和其他组织研发新药的合法权益。对首个挑战专利成功并首个获批上市的化学仿制药，给予市场独占期。国务院药品监督管理部门在该药品获批之日起12个月内不再批准同品种仿制药上市，共同挑战专利成功的除外。市场独占期限不超过被挑战药品的原专利权期限。
同时，在第39条中，“对首个挑战专利成功并首个获批上市的化学仿制药，给予市场独占期。”根据实施办法（试行）》的第11条，“挑战专利成功”的意思是“化学仿制药申请人提交四类声明，且根据其提出的宣告专利权无效请求，相关专利权被宣告无效，因而使仿制药可获批上市”。IPO建议在第39条中包括实施办法的定义以澄清“挑战专利成功”的定义。

故此，IPO建议下面的增加：

挑战专利成功是指化学仿制药申请人提交四类声明，且根据其提出的宣告专利权无效请求，相关专利权被宣告无效，因而使仿制药可获批上市。

第40条

IPO欢迎在第40条引入六年的“试验数据独占权”，但注意到这种保护似乎仅适用于“获批上市部分药品的未披露试验数据和其他数据实施保护”。IPO建议试验数据和药品范围有更明确的定义，以包括药品注册申请中包含的所有未公开数据。IPO建议进一步澄清或定义本条例中关于“其他数据”和“某些药物”的含义。

IPO同时注意到，出于“公共利益需要”，国家药品监督管理局可能有权披露未公开的试验数据。公共利益是不明确的，并可以有多种不同的解释。如果对公共利益做出了不恰当的解释，则试验数据独占权可能没有实际意义。IPO寻求澄清“公共利益”的含义。

进一步第，在“已采取措施确保该类数据不会被不正当地进行商业利用”的情况下，国家药品监督管理局也有权披露未公开的试验数据。IPO相信澄清此类“情况”的含义会有帮助。

IPO协会感谢中国国家药品监督管理局对我们在此提交的意见的关注，并欢迎进一步交流及提供进一步意见的机会。

随函附上本信的译文。

此致
敬礼！

Karen Cochran
美国只是产权所有人协会主席